Incyte's (INCY) Failure Does Not Derail the Core Dermatology Opportunity - Cowen
Tweet Send to a Friend
Cowen analyst, Marc Frahm, reiterated an Outperform rating on Incyte (NASDAQ: INCY) after the Phase III GRAVITAS-301 study failed to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
